Italian Oncologists Call on US Biotech to Launch Compassionate-Use Program for Pancreatic Cancer Drug
Aiom is urging US biotech company Revolution Medicines to launch a compassionate‑use program for daraxonrasib, a targeted therapy that has doubled survival in a pancreatic cancer trial. While the drug received FDA approval in the United States, no similar early‑access program exists in Europe, and Revolution Medicines has not submitted a registration dossier to the European Medicines Agency. Aiom and Italian oncologists argue the drug should be provided free of charge to Italian patients pending approval, citing ethical concerns over high import costs.